Viatris Swats Away Concerns Over Divestment Valuations
As US-Based Firm Updates On Glatiramer And Botox Biosimilar
Viatris remains committed to completing the sale of its global biosimilars unit to Biocon Biologics, while continuing efforts to generate up to $9bn in pre-tax proceeds by the end of 2023 from divestments.
